Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Poseida Therapeutics Inc (Poseida Therapeutics) is a biopharmaceutical company. It utilizes proprietary gene engineering platform, to develop cell and gene therapies to treat solid tumors and hematological malignancies. The company's product pipeline include P-PSMA-ALL01 for treatmane of solid tumors; and other drug programs such as P-BCMA-ALL01, P-BCMACD19-ALL01, P-CD19CD20-ALL01, and P-CD70=ALL01 to treat heme malignancies. Poseida Therapeutics is also investigating P-OTC-101, P-FVIII-101, and P-PAH-101 programs for liver diseases. The company works in collaboration with Roche. Poseida Therapeutics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
9390 Towne Centre Drive, Suite 200, San Diego, California, 92121
Website
poseida.com
Telephone
1 858 7793100
No of Employees
330
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PSTX (NASD)
Revenue (2022)
$64.7M
-50.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-92.9%
(2022 vs 2021)
Market Cap*
$335.5M
Net Profit Margin (2022)
XYZ
-288.9%
(2022 vs 2021)
* As of and is in US$
Poseida Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Solid Tumors: |
| P-MUC1C-ALLO1 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In May, the company signed an agreement with Xyphos Biosciences, Inc. to develop groundbreaking convertible CAR programs, leveraging the innovative cell therapy platforms of both companies. |
| 2020 | Stock Listings/IPO | In July, the company announced its plans to raise US$224 million in IPO of shares. |
| 2019 | Acquisitions/Mergers/Takeovers | In January, Poseida Therapeutics acquired Vindico NanoBiotechnology. |
Competitor Comparison
| Key Parameters | Poseida Therapeutics Inc | Astellas Pharma Inc | Adaptimmune Therapeutics Plc | bluebird bio Inc | Bellicum Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United Kingdom | United States of America | United States of America |
| City | San Diego | Chuo-Ku | Abingdon | Somerville | Houston |
| State/Province | California | Tokyo | England | Massachusetts | Texas |
| No. of Employees | 330 | 14,484 | 449 | 323 | 13 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark J. Gergen | Chairman | Executive Board | - | - |
| Kristin Yarema, Ph.D. | Chief Executive Officer; President | Senior Management | 2024 | - |
| Johanna Mylet | Chief Financial Officer | Senior Management | - | 36 |
| Harry J. Leonhardt | General Counsel; Chief Compliance Officer; Secretary | Senior Management | - | - |
| Syed Rizvi, M.D. | Chief Medical Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer